Aastrom Biosciences announces first trial of Tissue Repair Cells for regeneration of vascular tissue cells in diabetics.
The aim of the study is to evaluate the safety and ability of Aastrom's bone marrow-derived TRCs to regenerate functioning blood vessels in the legs of diabetic patients with limb ischemia. The company says it is intended that the patients may experience relief from clinical problems that are related to a loss of blood circulation, such as: deep "bed-sore type" ulcerated wounds of the feet, pain, immobility, and infection.
Over the 12 months following treatment, the trial will evaluate whether the TRC treatment results in improved or complete healing of ulcers, as well as whether amputation can be avoided or delayed. The trial will also monitor the time to relapse if complete healing is not attended, and whether the prognosis for patient survival improves, compared to standard of care controls.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||clinical trials|
|Comment:||Aastrom Biosciences announces first trial of Tissue Repair Cells for regeneration of vascular tissue cells in diabetics.(clinical trials)|
|Article Type:||Brief Article|
|Date:||Oct 15, 2005|
|Previous Article:||Atrium Medical, Isotechnika announce licensing agreements for use of new drugs with medical devices.|
|Next Article:||Biomedical Tissue Services being investigated for procuring tissues illicitly, falsifying testing records.|